PharmaCyte Biotech, Inc. Quarterly Liabilities in USD from Q1 2011 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.
Summary
PharmaCyte Biotech, Inc. quarterly Liabilities history and growth rate from Q1 2011 to Q2 2024.
  • PharmaCyte Biotech, Inc. Liabilities for the quarter ending July 31, 2024 was $17.2M, a 15.9% decline year-over-year.
Liabilities, Quarterly (USD)
Liabilities, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $17.2M -$3.24M -15.9% Jul 31, 2024 10-Q 2024-09-17
Q1 2024 $20.4M +$19.8M +3376% Apr 30, 2024 10-Q 2024-09-17
Q4 2023 $22.5M +$21.6M +2614% Jan 31, 2024 10-Q 2024-03-18
Q3 2023 $20.8M +$19.5M +1487% Oct 31, 2023 10-Q 2023-12-15
Q2 2023 $20.4M +$19.3M +1772% Jul 31, 2023 10-Q 2023-09-18
Q1 2023 $587K -$118K -16.7% Apr 30, 2023 10-K 2024-08-13
Q4 2022 $828K +$215K +35.1% Jan 31, 2023 10-Q 2023-03-16
Q3 2022 $1.31M +$1.13M +604% Oct 31, 2022 10-Q 2022-12-14
Q2 2022 $1.09M +$164K +17.8% Jul 31, 2022 10-Q 2022-09-14
Q1 2022 $704K -$20.4K -2.82% Apr 30, 2022 10-K 2023-07-31
Q4 2021 $613K -$35.7K -5.51% Jan 31, 2022 10-Q 2022-03-15
Q3 2021 $186K -$479K -72% Oct 31, 2021 10-Q 2021-12-14
Q2 2021 $925K -$262K -22.1% Jul 31, 2021 10-Q 2021-09-14
Q1 2021 $725K -$353K -32.7% Apr 30, 2021 10-K 2022-07-28
Q4 2020 $649K -$370K -36.3% Jan 31, 2021 10-Q 2021-03-12
Q3 2020 $665K -$139K -17.3% Oct 31, 2020 10-Q 2020-12-11
Q2 2020 $1.19M +$580K +95.7% Jul 31, 2020 10-Q 2020-09-11
Q1 2020 $1.08M +$335K +45.1% Apr 30, 2020 10-K 2021-08-10
Q4 2019 $1.02M +$548K +116% Jan 31, 2020 10-Q 2020-03-13
Q3 2019 $804K +$141K +21.4% Oct 31, 2019 10-Q 2019-12-23
Q2 2019 $607K -$276K -31.3% Jul 31, 2019 10-Q 2019-09-13
Q1 2019 $743K +$98.7K +15.3% Apr 30, 2019 10-K 2020-08-13
Q4 2018 $471K -$416K -46.9% Jan 31, 2019 10-Q 2019-03-14
Q3 2018 $662K +$95.4K +16.8% Oct 31, 2018 10-Q 2018-12-14
Q2 2018 $883K +$17.3K +1.99% Jul 31, 2018 10-Q 2018-09-12
Q1 2018 $644K +$63.9K +11% Apr 30, 2018 10-K 2019-08-13
Q4 2017 $887K +$309K +53.4% Jan 31, 2018 10-Q 2018-03-19
Q3 2017 $567K +$118K +26.3% Oct 31, 2017 10-Q 2017-12-14
Q2 2017 $866K +$409K +89.7% Jul 31, 2017 10-Q 2017-09-13
Q1 2017 $580K -$57.4K -9% Apr 30, 2017 10-K 2018-07-20
Q4 2016 $578K -$487K -45.7% Jan 31, 2017 10-Q/A 2017-03-13
Q3 2016 $449K -$631K -58.4% Oct 31, 2016 10-Q 2016-12-02
Q2 2016 $456K -$700K -60.5% Jul 31, 2016 10-Q 2016-09-06
Q1 2016 $638K -$883K -58.1% Apr 30, 2016 10-K 2017-07-27
Q4 2015 $1.07M +$687K +181% Jan 31, 2016 10-Q 2016-03-08
Q3 2015 $1.08M +$803K +290% Oct 31, 2015 10-Q/A 2016-01-19
Q2 2015 $1.16M +$785K +211% Jul 31, 2015 10-Q/A 2016-01-19
Q1 2015 $1.52M +$1.15M +307% Apr 30, 2015 10-K 2016-07-29
Q4 2014 $379K -$101K -21% Jan 31, 2015 10-Q 2015-03-13
Q3 2014 $277K -$714K -72.1% Oct 31, 2014 10-Q 2014-12-15
Q2 2014 $371K -$623K -62.6% Jul 31, 2014 10-Q 2014-09-15
Q1 2014 $374K -$3.42M -90.2% Apr 30, 2014 10-K/A 2016-01-19
Q4 2013 $479K -$3.42M -87.7% Jan 31, 2014 10-Q 2014-03-17
Q3 2013 $991K -$2.8M -73.9% Oct 31, 2013 10-Q 2013-12-16
Q2 2013 $994K -$3.03M -75.3% Jul 31, 2013 10-Q 2013-09-16
Q1 2013 $3.8M +$11K +0.29% Apr 30, 2013 10-K 2014-08-04
Q4 2012 $3.9M +$369K +10.4% Jan 31, 2013 10-Q 2013-03-26
Q3 2012 $3.79M +$269K +7.65% Oct 31, 2012 10-Q 2012-12-26
Q2 2012 $4.03M +$625K +18.4% Jul 31, 2012 10-Q 2012-09-19
Q1 2012 $3.79M +$398K +11.7% Apr 30, 2012 10-K 2013-07-29
Q4 2011 $3.53M Jan 31, 2012 10-Q 2012-03-21
Q3 2011 $3.52M Oct 31, 2011 10-Q 2011-12-15
Q2 2011 $3.4M Jul 31, 2011 10-Q/A 2011-09-20
Q1 2011 $3.39M Apr 30, 2011 10-K 2012-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.